Seeding and Continuous Biopharmaceutical Crystallisation (SCoBiC)
Lead Research Organisation:
Imperial College London
Department Name: Chemical Engineering
Abstract
Biotechnology has made significant advancements in the understanding of human genomics and proteomics revolutionising medical diagnosis, prevention and treatment. Advances and breakthroughs in target-oriented biotechnology research have been used to enhance the synthesis of a number of commercially significant products. It has been reported that there are over 6000 biopharmaceuticals currently in development, potentially worth in excess of $100's bn (£145bn in 2012). Despite the increasing successes in discovering protein-based medicines, their manufacture in a cost effective and reliable fashion remains a major industrial challenge, which currently limits the ability of the biopharmaceutical industry to deliver solutions to patients. The vision here is to develop a programme for process intensification and de-bottleneck of downstream bioprocessing (DSB), by implementation of Seeding and Continuous Biopharmaceutical Crystallisation (SCoBiC), for the separation and purification of biopharmaceuticals. The ambition of this proposed project to develop strategies for a continuous biocrystallisation process, including selective crystallisation directly from multicomponent fermentation broths by seeding, for whole antibodies and antibody fragments. The goal is to reduce manufacturing costs, provide for simpler processes while achieving the high purity of material achievable from multi step chromatography. This ambition is driven by the awareness that separation and purification processes represent one of the most time and cost-intense downstream operations in the manufacture of commercial biopharmaceutical products. This proposal will develop a continuous biocrystallisation platform as an alternative to conventional DSB, offering improvements to manufacturability, enabling higher throughput, lowering the product costs, an increase in product quality and stability, including opportunities for novel formulations and technologies.
Planned Impact
This research work will have a direct impact on the academic community and the commercial sector (biopharmaceutical manufacturing community, equipment manufacturers and computation modelling companies).
Findings from this research work may lead to an improved understanding of macromolecular nucleation and crystallisation. Scientists involve in work relating to structural determination will benefit directly, in the availability of new strategies to improve the likelihood and probability of crystallisation of complex macromolecules. This will have an impact on the wider community involved in protein structural studies, from the understanding of how proteins work to drug discovery. Work on preparation and characterisation of next generation nanotemplates will benefit material scientists. Whilst the scaling-up and development of a continuous platform, including modelling work, will directly benefit engineers.
It is likely that the research will also have a direct impact commercially. Biopharmaceutical manufacturing companies will have access to a new approach for the isolation and purification of proteins; which will lead to a reduction in manufacturing costs, improved stability of products and potentially ease of formulation. There will be opportunities developed from this research for instrumentation and equipment companies to provide solutions to the biopharmaceutical companies. I also expect that companies providing modelling software to benefit from the fundamental science developed in this research to improve their models, and further apply the approaches to biopharmaceuticals.
The improvements to downstream separation of biopharmaceuticals will inevitably reduce manufacturing costs, which currently can account up to 80% of production cost. This reduction in manufacturing cost should lead to reduced product costs, and possibly more accessible medicines for the patients.
The development of biopharmaceutical products has seen a significant acceleration in the pharmaceutical industry with a relatively high success rate. Over 20% of drugs in the market are discovered and developed in the UK. Many companies, including AZ, FDB, GSK, etc in the UK, have set-up dedicated business units in the area. The compounds considered range from monoclonal and domain antibodies to "smaller" antisense or doubled stranded siRNA oligonucleotides. The UK currently has a world-class pharmaceutical industry with trade exports of over £20b since 2009 (till date) and investing over 23% in R&D (highest in Europe). The global pharmaceutical and biologics market is expected to grow between 3-6% annually this decade. The UK is well placed to take a world-leading role in this exciting field, recognised by the inward investment, high level of R&D spend, and strong commitment from the government as reported in the Bioscience 2015 government report. Nevertheless, this aim is an aspiration objective with the USA maintaining a clear lead in biotechnology currently. This proposal has the potential to delivery innovative technology resulting in efficient manufacturing, producing high value products that are underpinned by scientific understanding and for which there is potential for global demand.
It is anticipated that the impact and benefit of the research, will start to be realised within the first couple of years of the programme. A prototype if planned for the later stage of the programme and will be tested at our industrial partner's site (FDB). If successful, the goal is to deliver biocrystallisation as an industrial bioseparation step within the next 10 years.
Findings from this research work may lead to an improved understanding of macromolecular nucleation and crystallisation. Scientists involve in work relating to structural determination will benefit directly, in the availability of new strategies to improve the likelihood and probability of crystallisation of complex macromolecules. This will have an impact on the wider community involved in protein structural studies, from the understanding of how proteins work to drug discovery. Work on preparation and characterisation of next generation nanotemplates will benefit material scientists. Whilst the scaling-up and development of a continuous platform, including modelling work, will directly benefit engineers.
It is likely that the research will also have a direct impact commercially. Biopharmaceutical manufacturing companies will have access to a new approach for the isolation and purification of proteins; which will lead to a reduction in manufacturing costs, improved stability of products and potentially ease of formulation. There will be opportunities developed from this research for instrumentation and equipment companies to provide solutions to the biopharmaceutical companies. I also expect that companies providing modelling software to benefit from the fundamental science developed in this research to improve their models, and further apply the approaches to biopharmaceuticals.
The improvements to downstream separation of biopharmaceuticals will inevitably reduce manufacturing costs, which currently can account up to 80% of production cost. This reduction in manufacturing cost should lead to reduced product costs, and possibly more accessible medicines for the patients.
The development of biopharmaceutical products has seen a significant acceleration in the pharmaceutical industry with a relatively high success rate. Over 20% of drugs in the market are discovered and developed in the UK. Many companies, including AZ, FDB, GSK, etc in the UK, have set-up dedicated business units in the area. The compounds considered range from monoclonal and domain antibodies to "smaller" antisense or doubled stranded siRNA oligonucleotides. The UK currently has a world-class pharmaceutical industry with trade exports of over £20b since 2009 (till date) and investing over 23% in R&D (highest in Europe). The global pharmaceutical and biologics market is expected to grow between 3-6% annually this decade. The UK is well placed to take a world-leading role in this exciting field, recognised by the inward investment, high level of R&D spend, and strong commitment from the government as reported in the Bioscience 2015 government report. Nevertheless, this aim is an aspiration objective with the USA maintaining a clear lead in biotechnology currently. This proposal has the potential to delivery innovative technology resulting in efficient manufacturing, producing high value products that are underpinned by scientific understanding and for which there is potential for global demand.
It is anticipated that the impact and benefit of the research, will start to be realised within the first couple of years of the programme. A prototype if planned for the later stage of the programme and will be tested at our industrial partner's site (FDB). If successful, the goal is to deliver biocrystallisation as an industrial bioseparation step within the next 10 years.
People |
ORCID iD |
Jerry Heng (Principal Investigator / Fellow) |
Publications
Bade I
(2023)
Crystal regeneration - a unique growth phenomenon observed in organic crystals post breakage.
in Materials horizons
Chen W
(2019)
High Protein-Loading Silica Template for Heterogeneous Protein Crystallization
in Crystal Growth & Design
Chen W
(2021)
Biopurification of monoclonal antibody (mAb) through crystallisation
in Separation and Purification Technology
Chen W
(2020)
Surface hydrophobicity: effect of alkyl chain length and network homogeneity
in Frontiers of Chemical Science and Engineering
Chen W
(2021)
Protein purification with nanoparticle-enhanced crystallisation
in Separation and Purification Technology
Gerard CJJ
(2022)
Template-Assisted Crystallization Behavior in Stirred Solutions of the Monoclonal Antibody Anti-CD20: Probability Distributions of Induction Times.
in Crystal growth & design
Guo M
(2022)
The effect of chain length and side chains on the solubility of peptides in water from 278.15 K to 313.15 K: A case study in glycine homopeptides and dipeptides
in Journal of Molecular Liquids
Guo M
(2021)
Triglycine (GGG) Adopts a Polyproline II (pPII) Conformation in Its Hydrated Crystal Form: Revealing the Role of Water in Peptide Crystallization.
in The journal of physical chemistry letters
Guo M
(2023)
The Effect of Chain Length and Conformation on the Nucleation of Glycine Homopeptides during the Crystallization Process.
in Crystal growth & design
Li X
(2021)
The critical role of agitation in moving from preliminary screening results to reproducible batch protein crystallisation
in Chemical Engineering Research and Design
Description | The purification of monoclonal antibody by biocrystallisation can be controlled by utilising nanotemplates. The research work has also demonstrated the role of impurities on the crystallisation of proteins in general, and more specifically for monoclonal antibodies. This can be useful in the development of purification strategies to improve the manufacturability of such systems. |
Exploitation Route | Development of new downstream separation routes for biopharmaceuticals, for example monoclonal antibodies/proteins to peptides. |
Sectors | Manufacturing including Industrial Biotechology Pharmaceuticals and Medical Biotechnology |
Description | We have worked with industry to apply the findings from this work for the crystallisation of other complex molecules, for example peptides and oligonucleotides, having some success in several of the systems we have investigated. This could potentially lead to new approaches for the purification and formulation of biopharmaceuticals. |
First Year Of Impact | 2022 |
Sector | Pharmaceuticals and Medical Biotechnology |
Impact Types | Economic |
Description | 1. EU MSCA International Fellowship |
Amount | € 225,000 (EUR) |
Funding ID | 101106785 |
Organisation | Marie Sklodowska-Curie Actions |
Sector | Charity/Non Profit |
Country | Global |
Start | 09/2023 |
End | 09/2025 |
Description | ATLAS - Automated high-throughput platform suite for accelerated molecular systems discovery |
Amount | £1,281,110 (GBP) |
Funding ID | EP/V029142/1 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 05/2021 |
End | 06/2024 |
Description | CASE Studentship - D Pessina |
Amount | £31,500 (GBP) |
Organisation | AstraZeneca |
Sector | Private |
Country | United Kingdom |
Start | 09/2022 |
End | 09/2026 |
Description | CSC PhD Scholarship |
Amount | £180,000 (GBP) |
Organisation | Ministry of Science and Technology |
Sector | Public |
Country | China |
Start | 09/2017 |
End | 09/2021 |
Description | EU MSCA International Fellowship |
Amount | € 225,000 (EUR) |
Funding ID | 101026339 |
Organisation | Marie Sklodowska-Curie Actions |
Sector | Charity/Non Profit |
Country | Global |
Start | 09/2021 |
End | 09/2023 |
Description | PhD studentship |
Amount | £118,612 (GBP) |
Organisation | BASF |
Sector | Private |
Country | Germany |
Start | 12/2022 |
End | 11/2026 |
Title | CCDC 2049957: Experimental Crystal Structure Determination |
Description | Related Article: Mingxia Guo, Ian Rosbottom, Lina Zhou, Chin W. Yong, Ling Zhou, Qiuxiang Yin, Ilian T. Todorov, Ethan Errington, Jerry Y. Y. Heng|2021|J.Phys.Chem.Lett.|12|8416|doi:10.1021/acs.jpclett.1c01622 |
Type Of Material | Database/Collection of data |
Year Produced | 2021 |
Provided To Others? | Yes |
URL | http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc26t4nv&sid=DataCite |
Title | Dataset for "High Protein-Loading Silica Template for Heterogeneous Protein Crystallization" |
Description | Characterization data of nanotemplate for protein crystallization. |
Type Of Material | Database/Collection of data |
Year Produced | 2019 |
Provided To Others? | Yes |
URL | https://zenodo.org/record/3856654 |
Title | Dataset for "High Protein-Loading Silica Template for Heterogeneous Protein Crystallization" |
Description | Characterization data of nanotemplate for protein crystallization. |
Type Of Material | Database/Collection of data |
Year Produced | 2019 |
Provided To Others? | Yes |
URL | https://zenodo.org/record/3856655 |
Description | EPSRC Directed Assembly Network Meeting |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Other audiences |
Results and Impact | A day meeting/workshop on nucleation and crystallisation, focusing on assembly and disassembly with a session which included AI. This was a very interactive day and participants drove the discussions leading on to some very interesting points highlighted. |
Year(s) Of Engagement Activity | 2017 |
Description | Hosting Year 11-12 students on week long placements in our laboratory |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | We hosted students (currently or will soon be doing A-levels) on a week long placement in our lab. The school students have the experience of research and work closely with both PhD and postdoctoral researchers in the group on projects relevant to this research funding. |
Year(s) Of Engagement Activity | 2018,2019 |
Description | LIYSF student visit |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Schools |
Results and Impact | Around 50 students on the LIYSF programme visited our laboratory where we demonstrated crystallisation experiments and efforts to develop biocrystallisation for the separation of new modalities. The experiments included demonstration of continuous and semi-autonomous operations. |
Year(s) Of Engagement Activity | 2023 |
Description | School Visit (Cuddington Croft) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | A visit to a primary school to talk about "Crystal Making" to year 1 students as part of the school's Science Week. The 60 pupils who attended were excited to meet real "scientists" and also had the opportunity to look at crystal samples with microscopes and made some "ice" crystals. The teacher reported that the visit was very successful and the students continued to discuss the topic (and other related science topics) for some days. |
Year(s) Of Engagement Activity | 2017 |
Description | The Great Exhibition Road Festival |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Our PDRA was part of a team showcasing new capabilities in autonomous operations for the development of therapeutics as part of the Great Exhibition Road Festival. |
Year(s) Of Engagement Activity | 2023 |